公开(公告)号：US20220381796A1

公开(公告)日：2022-12-01

申请号：US17747397

申请日：2022-05-18

Applicant: Abbott Laboratories

Inventor： Beth McQuiston ,  Saul Datwyler ,  Raj Chandran

IPC: G01N33/68

Abstract: Disclosed herein are methods, and kits for use in said methods, that aid in the diagnosis and evaluation of a pediatric subject for traumatic brain injury (TBI), using ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), glial fibrillary acidic protein (GFAP), or a combination thereof. Also disclosed herein are methods, and kits for use in said methods, that aid in determining whether a pediatric subject would benefit from and thus receive an imaging procedure, such as MRI or head computerized tomography (CT) scan based on the levels of GFAP, UCH-L1 or GFAP and UCH-L1.

公开(公告)号：US20210302441A1

公开(公告)日：2021-09-30

申请号：US17224685

申请日：2021-04-07

Applicant: Abbott Laboratories ,  Cedars-Sinai Medical Center

Inventor： Jennifer Van Eyk ,  Beth McQuiston ,  Saul Datwyler ,  Raj Chandran ,  Vidya Venkatraman ,  Shenyan Zhang

IPC: G01N33/68

Abstract: The present disclosure relates to methods for diagnosing and evaluating a subject that has sustained or may have sustained an injury to the head, such as a traumatic brain injury (TBI). In particular, the present disclosure identifies various biomarkers, the detection and/or differential expression of which can be used to assess the presence or absence of a TBI in a subject, and can be used as a basis for diagnosing a subject as having a specific type of TBI (e.g., severe TBI or subclasses of mild TBI). The various TBI biomarkers can be detected individually or in combination and can be used as an important diagnostic, prognostic, and/or TBI risk stratification tool as part of assessing a subject's TBI status.

公开(公告)号：US20210088533A1

公开(公告)日：2021-03-25

申请号：US17099668

申请日：2020-11-16

Applicant: Abbott Laboratories

Inventor： Beth McQuiston ,  Justin Rogers ,  Jaime Marino ,  Raj Chandran ,  Tianming Zhang ,  Saul Datwyler

IPC: G01N33/68 ,  A61B5/00 ,  A61B5/055

Abstract: Disclosed herein are methods that aid in the determination of whether to perform imaging, such as magnetic resonance imaging (MM) or computerized tomography (CT) scan, on a human subject that has sustained or may have sustained an injury to the head using an early biomarker, such as ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), glial fibrillary acidic protein (GFAP), or a combination thereof. These methods involve detecting levels and changes in levels of UCH-L1 in samples taken from a human subject at time points within 24 hours after the subject has sustained or may have sustained an injury to the head.

公开(公告)号：US20180313838A1

公开(公告)日：2018-11-01

申请号：US15963627

申请日：2018-04-26

Applicant: Abbott Laboratories

Inventor： Beth McQuiston ,  Justin Rogers ,  Saul Datwyler ,  Jaime Marino

IPC: G01N33/573 ,  G01N33/68 ,  A61B6/03 ,  A61B6/00

CPC classification number: G01N33/6896 ,  G01N2333/948 ,  G01N2800/28

Abstract: Disclosed herein are methods that aid in the hyperacute diagnosis and evaluation of a human subject that has sustained or may have sustained an injury to the head, such as mild, moderate, severe, or moderate to severe traumatic brain injury (TBI), using an early biomarker, such as ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), glial fibrillary acidic protein (GFAP), or a combination thereof. Also disclosed here are methods that aid in the hyperacute determination of whether a human subject that has sustained an injury or may have sustained to the head would benefit from and thus receive a head computerized tomography (CT) scan based on the levels of UCH-L1. These methods involve detecting changes of levels of an early biomarker, such as ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), glial fibrillary acidic protein (GFAP), or a combination thereof, in samples taken from a human subject at a time point within about 2 hours, such as about 10, 12, or 20 minutes, after the subject has sustained or may have sustained an injury to the head and a second time point about 3 hours to about 6 hours after the first sample is taken.

公开(公告)号：US20180106818A1

公开(公告)日：2018-04-19

申请号：US15723070

申请日：2017-10-02

Applicant: Abbott Laboratories

Inventor： Saul A. Datwyler ,  Beth McQuiston ,  Elaine Brate ,  John Ramp ,  David Pacenti

IPC: G01N33/68 ,  G01N33/535 ,  G01N33/566

Abstract: Disclosed herein are improved methods of assessing Glial fibrillary acidic protein (GFAP) status in a subject (such as for examples, as a measure of traumatic brain injury or for other clinical reasons).

公开(公告)号：US20180106800A1

公开(公告)日：2018-04-19

申请号：US15722970

申请日：2017-10-02

Applicant: Abbott Laboratories

Inventor： Saul A. Datwyler ,  Beth McQuiston ,  Gangamani Beligere ,  Elaine Brate ,  John Ramp ,  David Pacenti

IPC: G01N33/566 ,  G01N33/68

Abstract: Disclosed herein are improved methods of assessing ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) status in a subject (such as for example, as a measure of traumatic brain injury or for other clinical reasons). Also disclosed herein are methods of assessing a subject's glial fibrillary acid protein (GFAP) and UCH-L1 status in subject (such as, for example as a measure of traumatic brain injury or for other clinical reasons).

公开(公告)号：US20250020665A1

公开(公告)日：2025-01-16

申请号：US18792630

申请日：2024-08-02

Applicant: Abbott Laboratories

Inventor： Beth McQuiston ,  Justin Rogers ,  Jaime Marino ,  Raj Chandran ,  Tianming Zhang ,  Saul Datwyler

IPC: G01N33/68 ,  A61B5/00 ,  A61B5/055 ,  A61B6/03 ,  A61B6/50

Abstract: Disclosed herein are methods that aid in the determination of whether to perform imaging, such as magnetic resonance imaging (MRI) or computerized tomography (CT) scan, on a human subject that has sustained or may have sustained an injury to the head using an early biomarker, such as ubiquitin carboxy-terminal hydrolase L1 (UCH-L1), glial fibrillary acidic protein (GFAP), or a combination thereof. These methods involve detecting levels and changes in levels of UCH-L1 in samples taken from a human subject at time points within 24 hours after the subject has sustained or may have sustained an injury to the head.

公开(公告)号：US20250003988A1

公开(公告)日：2025-01-02

申请号：US18443416

申请日：2024-02-16

Applicant: Abbott Laboratories

Inventor： Beth McQuiston ,  Saul Datwyler ,  Raj Chandran ,  Jaime Marino ,  Hongwei Zhang

IPC: G01N33/68

Abstract: Disclosed herein are methods that aid in the determination of whether a subject has a traumatic brain injury (TBI) by detecting levels of at least one biomarker, such as ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) glial fibrillary acidic protein (GFAP), or a combination thereof, in samples taken from a subject, such as a human subject, where the subject has received a head CT scan that is negative for a TBI.

公开(公告)号：US20240426842A1

公开(公告)日：2024-12-26

申请号：US18640030

申请日：2024-04-19

Applicant: Abbott Laboratories ,  Cedars-Sinai Medical Center

Inventor： Jennifer Van Eyk ,  Beth McQuiston ,  Saul Datwyler ,  Raj Chandran ,  Vidya Venkatraman ,  Shenyan Zhang

IPC: G01N33/68

Abstract: The present disclosure relates to methods for diagnosing and evaluating a subject that has sustained or may have sustained an injury to the head, such as a traumatic brain injury (TBI). In particular, the present disclosure identifies various biomarkers, the detection and/or differential expression of which can be used to assess the presence or absence of a TBI in a subject, and can be used as a basis for diagnosing a subject as having a specific type of TBI (e.g., severe TBI or subclasses of mild TBI). The various TBI biomarkers can be detected individually or in combination and can be used as an important diagnostic, prognostic, and/or TBI risk stratification tool as part of assessing a subject's TBI status.

公开(公告)号：US20240369579A1

公开(公告)日：2024-11-07

申请号：US18766065

申请日：2024-07-08

Applicant: Abbott Laboratories

Inventor： Jamie Becnel ,  Saul A. Datwyler ,  Stacey Pazar Huth ,  Beth McQuiston ,  Jackie A. Garritty ,  Evan McCormick

IPC: G01N33/68 ,  G01N33/543 ,  G01N33/573

Abstract: Disclosed herein are methods and devices for performing at least one lateral flow assay on a biological sample obtained from a subject to determine an amount or presence of ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) alone, or an amount or presence of UCH-L1 and an amount or presence of glial fibrillary acidic protein (GFAP).